Schwartz, Morton A.

Mayo Clinic

Univ of Pennsylvania, Philadelphia, PA; Dana-Farber Cancer Inst, Boston, MA; Fox Chase Cancer Ctr, Philadelphia, PA; Thomas Jefferson Univ, Philadelphia, PA; Mayo Clinic, Rochester, MN; Mount Sinai Medcl Ctr, Miami, FL; Northwestern Univ, Chicago, IL

High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200

Giantonio, Bruce J. , Catalano, Paul J. , Meropol, Neal J. , Mitchell, Edith P. , Schwartz, Morton A., Benson, Al B. , O’Dwyer, P J , Alberts, Steven R.

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 2-2

10.1200/jco.2005.23.16_suppl.2

Schwartz, Morton A.

Citations 1

High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200

Giantonio, Bruce J. , Catalano, Paul J. , Meropol, Neal J. , Mitchell, Edith P. , Schwartz, Morton A., Benson, Al B. , O’Dwyer, P J , Alberts, Steven R.